Showing 1361-1370 of 1616 results for "".
- Radiance Therapeutics to Present at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/radiance-therapeutics-to-present-at-glaucoma-360-new-horizons-forum/2481398/Radiance Therapeutics announced that Laurence Marsteller, MD, Chief Executive Officer, will present the company at the Glaucoma Research Foundation headline event, Glaucoma 360 New Horizons 2023, that will take place on February 3, 2023 in San Francisco. The Radiance Therapeut
- Clearside Biomedical Announces Leadership Changeshttps://modernod.com/news/clearside-biomedical-announces-leadership-changes/2481386/Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, MD, will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ci
- Eyenovia: Positive Evidence that Optejet Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Dropshttps://modernod.com/news/eyenovia-positive-evidence-that-optejet-delivery-technology-decreased-inflammation-from-preserved-glaucoma-solutions-compared-to-drops/2481349/Eyenovia announced results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatm
- AcuFocus Announces First Commercial Patients Treated With the IC-8 Apthera IOLhttps://modernod.com/news/acufocus-announces-first-commercial-patients-treated-with-the-ic-8-apthera-iol/2481329/AcuFocus announced that Vance Thompson, MD, of Vance Thompson Vision, Sioux Falls, South Dakota has commercially implanted the first patients with the IC-8 Apthera IOL. The first and only small aperture, non-toric extended depth of focus IOL, the Apthera IOL is FDA approved fo
- EyeCare Partners Expands Footprint in Oklahoma with Retinal Associates of Oklahomahttps://modernod.com/news/eyecare-partners-expands-footprint-in-oklahoma-with-retinal-associates-of-oklahoma/2481328/EyeCare Partners (ECP) announced that it has expanded its presence in Oklahoma through a partnership with Retinal Associates of Oklahoma (RAO). Terms of the deal were not disclosed. The ECP network welcomes Darin R. Haivala, MD, and Rob
- ViaLase Makes Several Appointments to its Executive Teamhttps://modernod.com/news/vialase-makes-several-appointments-to-its-executive-team/2481244/ViaLase announced the appointments of Tom Frinzi as Executive Chairman of the Board; Richard Lewis, MD, as Chief Medical Officer; Shawn O'Neil as Chief Commercial Officer; and Brendan O'Herlihy as Vice President, Global Commercial Operations. The executives w
- LSU Health New Orleans Develops New Human Cell Line to Study Blinding Eye Disordershttps://modernod.com/news/lsu-health-new-orleans-develops-new-human-cell-line-to-study-blinding-eye-disorders/2481175/Under the direction of Boyd Professor Nicolas Bazan, MD, PhD, scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. Called ABC, these cells so closely resemble and retain the properties of n
- Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/glaukos-technologies-featured-in-numerous-scientific-abstracts-at-the-2022-american-academy-of-ophthalmology-annual-meeting/2481136/Glaukos announced that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30-October 3, 2022 in Chicago. Key Glaucoma Presentations: Bryan CH Ang, MD Novel
- EyeCare Partners Launches New Innovation Centerhttps://modernod.com/news/eyecare-partners-launches-new-innovation-center/2481118/EyeCare Partners (ECP) announced the launch of the EyeCare Partners Innovation Center, which aims to improve the delivery and quality of eye care and advance clinical eye health education. The Innovation Center will be led by ECP’s Chief Clinical Officer, Antonio Capone, Jr., MD.
- Isarna Therapeutics Presents Update From Phase 2 BETTER Study in Wet AMD and DME at the EURETINA Meetinghttps://modernod.com/news/isarna-therapeutics-presents-update-from-phase-2-better-clinical-study-in-wet-amd-and-dme-at-the-euretina-meeting/2481056/Isarna Therapeutics presented an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Marion Munk, MD, PhD, FEBO, and the CMO of Isarna Therapeutics provided initial positive safety results and effic